RGNCY-0075 (CAD-31 neuroprotector)

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

CAD-31 has enhanced neurogenic activity in human neural precursor cells (NCPs).  It also stimulates the division of NCPs in the subventricular zone of old APPswe/PS1∆E9 mice when fed from an early age as a preventative strategy.  Pharmacological and preliminary toxicology studies show that AD-31 is brain penetrant and likely to be safe.  When CAD-31 is fed to old and symptomatic  APPswe/PS1∆E9 AD mice starting at 10 months of age for 3 months, there is a reduction in memory deficit and brain inflammation, as well as an increase in the expression of synaptic proteins.  Metabolic data from brain and plasma shows that the major effect of CAD-31 is on fatty acid metabolism and inflammation.  Furthermore, CAD-31 has significant effects on synapse formation and AD-metabolic pathways.  CAD-31 effectively prevents some of the toxic events in old age-associated neurodegenerative disease.

SMILE:  OC1=CC=CC(/C=N/N(C2=CC=C(C)C=C2C)C(C(F)(F)F)=O)=C1

Systematic Name (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-hydroxybenzylidene)acetohydrazide 

Molecular Weight:  336.31

Formula: C17H15F3N2O

PMID:  28709449

Tags: Alzheimer’s, Alzheimers, neuroprotection, Memory, RGNCY-0075, CAD-31, CAD